MX2019002057A - Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. - Google Patents

Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.

Info

Publication number
MX2019002057A
MX2019002057A MX2019002057A MX2019002057A MX2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A
Authority
MX
Mexico
Prior art keywords
solid forms
cenicriviroc mesylate
processes
cenicriviroc
mesylate
Prior art date
Application number
MX2019002057A
Other languages
English (en)
Spanish (es)
Inventor
Ian Cooper Martin
Phiasivongsa Pasit
Kay Sharp Emma
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MX2019002057A publication Critical patent/MX2019002057A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019002057A 2016-08-31 2017-08-30 Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. MX2019002057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
MX2019002057A true MX2019002057A (es) 2019-11-18

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002057A MX2019002057A (es) 2016-08-31 2017-08-30 Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.

Country Status (13)

Country Link
US (1) US10301287B2 (https=)
EP (1) EP3506896A4 (https=)
JP (2) JP2019526628A (https=)
KR (1) KR20190057066A (https=)
CN (1) CN110167550A (https=)
AU (1) AU2017321594A1 (https=)
BR (1) BR112019003987A2 (https=)
CA (1) CA3034606A1 (https=)
MX (1) MX2019002057A (https=)
RU (1) RU2019109019A (https=)
SG (1) SG11201901438VA (https=)
TW (1) TW201823235A (https=)
WO (1) WO2018045043A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11613670B2 (en) 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11298876B2 (en) 2018-06-19 2022-04-12 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
KR20210053921A (ko) * 2018-08-31 2021-05-12 에보니크 오퍼레이션즈 게엠베하 중합체 분말을 제조하는 방법
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US12466817B2 (en) 2020-05-22 2025-11-11 Nicoya Therapeutics (Shanghai) Co., Ltd Pyridine derivative and application thereof
US20240124690A1 (en) * 2021-02-22 2024-04-18 Asahi Kasei Kabushiki Kaisha Composition Containing Cellulose Nanofibers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CA2191980A1 (en) 1994-07-04 1996-01-18 Takashi Sohda Phosphonic acid compounds, their production and use
US6172061B1 (en) 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
PE20030329A1 (es) 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
JP2004123694A (ja) * 2002-03-12 2004-04-22 Takeda Chem Ind Ltd 光学活性スルホキシド誘導体の製造法
WO2005089714A1 (ja) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CN103402998B (zh) 2010-11-18 2017-09-26 耶鲁大学 具有募集抗体并对人体免疫缺陷病毒进入有抑制活性的双功能分子
JP2015520144A (ja) 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトAkron Molecules Ag 疼痛の治療のための化合物の使用
CN105263498B (zh) 2013-05-15 2019-04-26 妥必徕疗治公司 赛尼克韦罗组合物及其制备和使用方法
HK1232147A1 (zh) 2014-03-21 2018-01-05 Tobira Therapeutics, Inc. 用於治疗纤维化的赛尼克韦罗
US20170105969A1 (en) * 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス, インコーポレイテッド セニクリビロックの製造方法及び関連類似体

Also Published As

Publication number Publication date
EP3506896A4 (en) 2020-08-26
EP3506896A1 (en) 2019-07-10
CA3034606A1 (en) 2018-03-08
WO2018045043A1 (en) 2018-03-08
TW201823235A (zh) 2018-07-01
CN110167550A (zh) 2019-08-23
RU2019109019A3 (https=) 2021-08-23
BR112019003987A2 (pt) 2019-05-28
KR20190057066A (ko) 2019-05-27
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21
SG11201901438VA (en) 2019-03-28
US20180057481A1 (en) 2018-03-01
US10301287B2 (en) 2019-05-28
RU2019109019A (ru) 2020-10-01
AU2017321594A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (es) Polinucleotidos moduladores.
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MX2019001313A (es) Composiciones farmaceuticas.
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
WO2016011222A3 (en) Circular polynucleotides
WO2016011306A3 (en) Terminal modifications of polynucleotides
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
MX2018008424A (es) Compuestos antiproliferativos y sus composiciones farmaceuticas y usos.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019005855A (es) Formulaciones que se pueden pulverizar.
IL264386B1 (en) New formulations and mixtures of cannabis tablets and methods of making them
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2014CH00840A (https=)
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
PL3468964T3 (pl) Modulatory soce, ich kompozycje i zastosowania
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
EP4582145A3 (en) Solid state forms of ixazomib citrate